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Abstract
Background:  Alternative splicing contributes significantly to the complexity of the human
transcriptome and proteome. Computational prediction of alternative splice isoforms are usually
based on EST sequences that also allow to approximate the expression pattern of the related
transcripts. However, the limited number of tissues represented in the EST data as well as the
different cDNA construction protocols may influence the predictive capacity of ESTs to unravel
tissue-specifically expressed transcripts.
Methods: We predict tissue and tumor specific splice isoforms based on the genomic mapping
(SpliceNest) of the EST consensus sequences and library annotation provided in the GeneNest
database. We further ascertain the potentially rare tissue specific transcripts as the ones
represented only by ESTs derived from normalized libraries. A subset of the predicted tissue and
tumor specific isoforms are then validated via RT-PCR experiments over a spectrum of 40 tissue
types.
Results: Our strategy revealed 427 genes with at least one tissue specific transcript as well as 1120
genes showing tumor specific isoforms. While our experimental evaluation of computationally
predicted tissue-specific isoforms revealed a high success rate in confirming the expression of these
isoforms in the respective tissue, the strategy frequently failed to detect the expected restricted
expression pattern. The analysis of putative lowly expressed transcripts using normalized cDNA
libraries suggests that our ability to detect tissue-specific isoforms strongly depends on the
expression level of the respective transcript as well as on the sensitivity of the experimental
methods. Especially splice isoforms predicted to be disease-specific tend to represent transcripts
that are expressed in a set of healthy tissues rather than novel isoforms.
Conclusions: We propose to combine the computational prediction of alternative splice isoforms
with experimental validation for efficient delineation of an accurate set of tissue-specific transcripts.
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Background
The large difference between cells from different tissues is
the consequence of a complex regulatory machinery guid-
ing the tissue specific expression of genes and their tran-
scripts. Several genes have been described to exhibit
differential splicing patterns for different tissues (E.g.
PDE1C [1]; IRF-3 [2]) that result either in alternative pro-
teins or affect the regulation of the respective gene product
[3]. Due to the large number of genes generating alterna-
tive transcripts as well as by the complicated splicing
machinery involving a large variety of different proteins,
mis-splicing events are also frequently observed. Some of
these artificial splice isoforms are already linked to spe-
cific diseases like Hemophilia A, Marfan syndrome etc.
[4,5].
The resource mainly used to predict tissue-specific expres-
sion is the rapidly expanding repertoire of expressed
sequence tags (ESTs) in the public databases representing
a wide spectrum of tissue types. Unlike serial analysis of
gene expression (SAGE) which mainly yields the tissue
specific expression of genes [6], the EST data additionally
allow the identification of alternatively spliced transcripts
[7-11].
Besides the detection of the existence of alternative splice
isoforms the tissue annotation of ESTs can be used for the
computational prediction of the expression pattern of
these transcripts where the tissue-wise count of transcript-
specific ESTs with respect to a random background distri-
bution defines an expression level [12-14]. Transcripts
that are significantly over-represented by ESTs derived
from a single tissue are usually defined as being tissue-spe-
cifically expressed. However, different cDNA construction
protocols like normalization [15] include subtractive
hybridization and PCR amplification steps introducing an
artificial enrichment of ESTs from lowly abundant tran-
scripts. The level of enrichment depends on the number of
normalization/amplification steps performed, measured
as Cot or Rot [16]. This inconsistency in the correlation of
the number of ESTs observed for a transcript and its real
expression level may affect the reliability of computa-
tional predictions of tissue-specifically expressed tran-
script. Since the EST-based prediction of expression
patterns might already be error-prone because of the lack
of sufficient numbers of EST sequences for each tissue this
might be further complicated by different cDNA library
protocols. Consequently, EST data related to normalized
cDNA libraries are excluded from analysis in several com-
putational approaches that aim at predicting tissue-spe-
cific expression [13,17]. Because of these uncertainties we
combined our computational prediction of alternative
splice variants and their expression pattern with experi-
mental validation of these iso-forms via RT-PCR on 40 dif-
ferent tissue samples in order to evaluate the predictive
potential of ESTs.
Results
The EST-based prediction of alternative splice iso-forms
revealed 427 genes each contributing at least one poten-
tial tissue-specifically expressed variant. These variants
show specificity for 28 different tissue types, where brain,
testis and placenta account for approximately half of these
transcripts (see additional file 1). Many of these genes (n
= 210) exhibit isoforms that were exclusively detected due
to ESTs derived from normalized libraries. These form a
significant fraction (p-value: 8e-19) of the total genes that
show tissue specific transcripts, since the number of ESTs
derived from normalized libraries (896,645) is only 30%
the total EST count (3,084,576) in tissues for which tissue
specific isoforms exist.
Out of the 20 isoforms tested experimentally (see addi-
tional file 3 for details of experiments), 15 isoforms could
be successfully verified in some tissue (Table 1). The
remaining five variants are either likely to resemble rare
transcripts according to the respective library construction
protocol, or as in case of a disease-specific isoform
(Hs.272688), the appropriate tissue sample was not avail-
able for experimental testing. Only four of the isoforms
predicted based on the basis of normalized libraries could
be validated using the standard RT-PCR conditions. For
five additional isoforms a more refined protocol had to be
applied in order to detect bands of significant strength.
More sensitive PCR conditions frequently revealed expres-
sion in more tissues indicating low expression of the iso-
forms in these tissues. These results show the tendency of
normalized libraries to be enriched for low-abundant
transcripts.
The predicted expression of the isoforms in a single tissue
could not be confirmed for half of the variants analyzed
(standard conditions). However, the isoforms were
always detected to be expressed in the tissue that was orig-
inally predicted by our software. The observed expression
pattern of the 'unspecific' isoforms ranges from expression
in only a few, sometimes related tissues (LMO7 [18]:
brain, eye, testis, Fig. 2; HRD1: brain, eye, thymus, salivary
gland, kidney) to ubiquitous expression (MRPL42,
ISGF3G). Those variants that were validated to be specifi-
cally expressed frequently originate from testis. Increasing
the sensitivity of the RT-PCR revealed another testis-spe-
cific variant. At the same time the variants of the genes
WNK1 and SCML1 were no longer defined as being tissue-
specifically expressed since they were now also detected in
a few additional tissues (Table 1: isoform 11 & 12).
The number of genes with transcripts exclusively
expressed in tumors is relatively large (1120) as comparedBMC Genomics 2004, 5:72 http://www.biomedcentral.com/1471-2164/5/72
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to the number of genes revealing tissue specific isoforms.
Interestingly, 2 out of 4 such disease-related transcripts
(Table 1: isoform 17–20) were ubiquitously expressed
although the large number of ESTs covering these variants
was suggesting a high significance of the prediction. The
tumor associated isoform described by Wang et al. [19]
was observed to be expressed in several fetal tissues along
with ovary.
The entire dataset for human as well as the gel images
from the RT-PCR experiments is available at http://splice
nest.molgen.mpg.de/Hs7/tissue-tumor-specificity.html.
Discussion
Consistent with previous work [11] our approach of com-
bining computational and experimental validation yields
a high success rate in predicting the existence of splice
variants. In line with the expected general enrichment of
clones derived from lowly expressed transcripts in nor-
malized cDNA libraries our experimental results confirm
the expression of the predicted low abundance transcripts.
Consequently, those isoforms that could not be validated
experimentally may also reflect real biological signatures
of extremely rare transcripts since they are often repre-
sented just by heavily normalized libraries (Cot 230,
CIDE-A + Hs.48396). While the methods used in the con-
struction of normalized libraries (PCR amplification,
Table 1: RT-PCR validation results for tissue and disease-specific splice isoforms. The experiments are categorized into three groups 
viz. tissue specific isoforms predicted via ESTs related to non-normalized libraries (1 to 4), tissue specific isoforms predicted only via 
ESTs derived from normalized libraries (5 to 16) and disease-specific isoforms (17 to 20). For some of the variants represented by 
normalized libraries, standard PCR did not reveal the isoforms. However, five of these isoforms were detected using refined PCR 
conditions. The experiments frequently validated the isoforms and the tissue type, but the predicted specificity was rarely verified.
Isoform Gene Chr. Unigene EST 
Evidence
ESTs Cycles Isoform Specificity Comment 
(Most sensitive 
PCR)
Norm. Level
1 Unknown 11 Hs.112250 testis 3 39 + +
2 ISGF3G 14 Hs.1706 stomach 10 39 + - Ubiquitous
3 MRPL42 12 Hs.112110 stomach-
lymph
5 39 + - Ubiquitous
4 SGN3 17 Hs.6076 testis 3 39 - ?
5 PC326 13 Hs.279882 testis 9 39 + + testis [36] Rot-5
6 LMO7 13 Hs.5978 brain 5 39 + - brain, testis, 
eye(?) [18]
7 HRD1 8 Hs.274122 brain 3 39 + - brain, eye, 
thymus, salivary 
gland, kidney
8 Unknown 1 Hs.24119 pancreas 4 39 + - approx. 10 
tissues
Cot-20
9 BCLG 12 Hs.11962 testis 4 39,78 ?,+ +,+ Cot-5
10 RBPMS 8 Hs.80248 placenta 4 39,78 ?,+ -,- Ubiquitous
11 SCML1 X Hs.109655 testis 12 39,78 ?,+ +,- approx. 6 
tissues
Rot-5
12 WNK1 12 Hs.432900 kidney 3 39,78 ?,+ +,- Digestive 
system [28]
Cot-25
13 NY-CO-
10
5 Hs.23557 testis 3 39,78 -,+ ?,+ Cot-5
14 Unknown 11 Hs.169100 testis 3 39,78 -,- ?,? Rot-5
15 Unknown 16 Hs.48396 breast 4 39,78 -,- ?,? Cot-230
16 CIDE-A 18 Hs.249129 breast 4 39,78 -,- ?,? Cot-230
17 KCNAB2 1 Hs.298184 tumor 29 39 + - Ubiquitous
18 SNRP70 19 Hs.174051 stomach 
ascites
25/26 39 + - Ubiquitous
19 RAB1 14 Hs.227327 tumor 39/95 39 + - fetal(kidney, 
thymus, liver, 
spleen), ovary 
[19]
20 Unknown 7 Hs.272688 tumor 12 39,78 -,- ?,? relevant tumor 
sample not in 
setBMC Genomics 2004, 5:72 http://www.biomedcentral.com/1471-2164/5/72
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subtraction, size selection) increase the sensitivity of the
detection of transcripts they unfortunately disturb the
rough correlation between the expression level of a tran-
script and the observed number of related clones that is
usually maintained in non-normalized libraries. There-
fore, in these cases, the larger number of ESTs found for a
specific transcript will profess to deal with a higher
expressed transcript, also implying a higher confidence in
the prediction although the sequences may be derived
from the same although amplified clone.
From the computational point of view the artificially
increased number of ESTs affects the likelihood to predict
tissue-specifically expressed transcripts since the predic-
tion mainly relies on the count of ESTs [12,13]. Neverthe-
less, our experimental results show that especially
isoforms predicted to be expressed exclusively in testis
could be successfully validated, while other isoforms fre-
quently appear to be expressed in a set of additional tis-
sues that were not suggested by the ESTs. Surprisingly, the
absence of supporting EST evidence for the variants LMO7
and ISGF3G is not caused by the lack of the respective
cDNA libraries but may rather reflect differences in the tis-
sue samples (e.g. enrichment of different cell types from
the same organ, developmental differences) used for
library construction.
In the context of tumors, our data shows that the pre-
dicted tumor-specific expression of isoforms derived from
ESTs usually tends not to reflect the experimentally vali-
dated expression pattern. Rather it suggests expression in
a collection of different tissues although the large number
of related ESTs derived from tumor would imply a high
confidence in the EST based prediction. Since tumor cells
Detection of brain specific splicing in gene LMO7 Figure 1
Detection of brain specific splicing in gene LMO7. The top part of the figure is a visualization of gene LMO7 in Splice-
Nest, showing parts of three transcripts with exons displayed as red blocks, connected by lines representing introns. The mid-
dle exon of the top transcript (Hs5978.1) is missing in the second transcript (Hs5978.2) and is therefore highlighted as an 
alternative splice event (green bar). The boundaries corresponding to this exon as well as the corresponding intron are visual-
ized as vertical lines in the GeneNest database (left and right box respectively). Both regions are covered by several ESTs 
depicted by horizontal arrows with corresponding tissues encoded in coloured rectangles towards the left of each EST. Upon 
comparing the tissue distribution of these alternative regions it is evident that the middle exon of transcript Hs5978.1 is cov-
ered by ESTs derived from several tissues, while the corresponding exon junction that lacks this middle exon, in transcript 
Hs5978.2, is represented by ESTs derived from brain only, thereby revealing this as a brain specific splice event.BMC Genomics 2004, 5:72 http://www.biomedcentral.com/1471-2164/5/72
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often show an up-regulation of a larger number of tran-
scripts involved in various pathways [20,21] the tumor-
specific transcripts predicted based on the EST data may
just reflect this general deregulation of gene expression.
The large number of predicted tumor-related isoforms fur-
ther supports this hypothesis. Nevertheless, some tran-
scripts detected via EST data may still serve as potential
tumor markers like in case of the gene PRAME [22] where
the EST data as well as the experimental data suggests spe-
cific expression in testis and in a variety of different
tumors (see additional file 2).
Overall, ESTs are an extremely powerful tool to reliably
unravel alternative transcripts independent of the level of
expression. The functional relevance of the low abundant
transcripts is not yet clear, especially if the isoforms do not
affect the coding sequence. These isoforms may either be
related to processes like nonsense-mediated decay (NMD:
[23,24]) or they might be some kind of non-functional
leakage of the splicing machinery. Nevertheless, since
many lowly expressed genes are already known to have
important regulatory functions [25-27] this may also hold
true for a not yet defined fraction of the alternative iso-
forms we detected via normalized libraries. In contrast to
the prediction of the existence of isoforms, the task of pre-
dicting their expression pattern is much more error-prone
since EST data always covers only a subset of potential tis-
sues with variable sensitivity. The fuzzy terminology of
tissue-specific expression that is frequently used to
describe significant expression in a discrete tissue or a set
of tissues, is therefore strongly biased by the sensitivity of
computational and experimental methods (SCML1;
WNK1 [28]). Beside these technical difficulties, the defini-
tion of specificity may also depend on the regulatory net-
work that mediates tissue-specificity. While isoforms
expressed in testis are specifically expressed in a more
strict sense, other isoforms are expressed in a small set of
(not necessarily related) tissues eventually pointing to
alternative regulatory mechanisms acting with different
stringency, e.g. involving transcription factors [29], [30]
and/or DNA methylation [31,32].
Conclusions
The separate evaluation of EST data from non-normalized
as well as from normalized cDNA libraries will help to cat-
egorize transcripts into highly and lowly abundant ones
thus facilitating the integration of EST-based predictions
with expression data from microarray experiments. We
suggest that large-scale analysis of tissue-specific tran-
scripts should be ideally based on a computational predic-
tion of isoforms that ranks candidate transcripts, tightly
coupled with experimental validation via RT-PCR or DNA
microarray experiments [33]. Such an approach will lead
to a comprehensive set of verified isoforms suitable for a
wide range of applications in the functional analysis of
the regulation of tissue-specific expression. This will also
improve the detection of tumor-related isoforms that do
not just reflect a general up-regulation of gene expression.
Methods
The basis of our work is the tissue/tumor annotation of
ESTs is GeneNest database [34] and the quality prediction
of alternative splicing [11], visualized in SpliceNest data-
base [10].
Library classification
The cDNA libraries of the GeneNest database were semi-
automatically categorized into non-normalized, normal-
ized/subtracted and PCR-based libraries by screening for
the appropriate keywords in the original annotation of
the respective EMBL database entries. All libraries for
which none of the keywords were found were defined as
being non-normalized. PCR-based libraries like those
derived by ORESTES PCR were not used for the current
analysis. Additionally, to avoid miscounting caused by
PCR amplification, ESTs of the same library and with
identical start/end positions in the alignment were treated
as a single sequence. Since the level of normalization of
different libraries may differ depending on the number of
rounds of subtractive hybridizations performed, we also
extracted the normalization level (measured as Cot or Rot:
[16]) as far as it was noted in the respective entries.
Increasing Cot-values hereby reflect the enrichment of
clones derived from low abundant transcripts in the
respective cDNA library. Besides the categorization of
cDNA libraries according to the construction methods
used we further split these groups into libraries derived
from healthy or disease tissue. Finally, ESTs of the four
groups of cDNA libraries (healthy/non-normalized,
healthy/normalized, disease/non-normalized, disease/
normalized) were either analyzed separately or data of
normalized and non-normalied libraries were combined.
Prediction of tissue specific alternative splicing
Alternative splice isoforms in the SpliceNest database are
revealed by aligning EST consensus sequences (putative
transcripts) related to one gene to the appropriate
genomic sequence. Significant differences in the bounda-
ries of the putative exons are interpreted as alternative
splicing events. For all exon-exon-boundaries that define
a certain splice iso-form the annotation of ESTs covering
the respective boundary is evaluated. Isoforms overrepre-
sented by ESTs from particular tissue are tagged as putative
tissue/tumor specific splice isoforms. Several parameters
(e.g. number of ESTs from a particular tissue, number of
ESTs from other tissues, number of associated mRNA
sequences etc.) are computed for these isoforms and
finally stored in a relational database system. The refined
set of tissue and tumor specific variants is then generated
by setting the requirement of at least 3 ESTs in bothBMC Genomics 2004, 5:72 http://www.biomedcentral.com/1471-2164/5/72
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RT-PCR validation experiment of a putative brain-specific isoform (LMO7) Figure 2
RT-PCR validation experiment of a putative brain-specific isoform (LMO7). (A) The additional exon is detected in 
all tissues (primers F1, R1). (B) The primer pair F1-R2 located on exons flanking the extra exon results in two products where 
the shorter one is observed in brain, testis and eye (weak band). The predicted brain-specific expression pattern is, in fact, not 
specific.BMC Genomics 2004, 5:72 http://www.biomedcentral.com/1471-2164/5/72
Page 7 of 8
(page number not for citation purposes)
alternative forms. Fig. 1 describes such a prediction using
GeneNest and SpliceNest visualizations. Since the counts
of ESTs per tissue-specific splice event were frequently
below 5, we considered it inappropriate to apply statisti-
cal methods as were used by Xu et. al. ([12]).
Experimental verification
A set of putative tissue specific (n = 16) and disease-
related (n = 4) alternative splice events was arbitrarily
selected for RT-PCR experiments. PCR primers were gen-
erated on the alternatively spliced exon as well as on either
side of the event (Fig. 2) using the primer design software
GenomePRIDE ([35]).
For the subsequent RT-PCR experiment, total RNA was
prepared using the single-step guanidinum method
according to the manufacturer's instructions (TRIZOL,
Gibco BRL). First strand cDNA synthesis was carried out in
20 µl reaction using the Omniscript Reverse transcriptase
(Qiagen) and the oligo(dT) primers with 2 µg of total
RNA. RT-PCR was carried out in a 20 µl reaction in 1 ×
buffer [1.5 mM Mg2+, 0.2 mM dNTPs, 0,4 µM primers
each, 1 Unit of Taq polymerase (Roche)] and 1 µl of
cDNA. Amplification steps were as follows: 95°C for 90
sec; 9 cycles of 94°C for 20 sec, 64°C for 10 sec decreasing
the annealing temp for 1°C with each cycle (touchdown),
72°C for 20 sec; followed by 30 cycles of 94°C for 20 sec,
55°C for 10 sec, 72°C for 20 sec, followed by an extension
at 72°C for 10 min. For the refined PCR, the amplification
step was repeated with identical PCR conditions but with
2 µl of PCR product instead of 1 µl of cDNA.
All PCR products were resolved on 2% agarose gels run at
90 V/20 cm for 1.5 h in TAE buffer. Gels were then manu-
ally examined for exact size, genomic contamination and
the tissues in which the bands are observed. As a control,
a fraction of variants were sequenced using the ABI Prism
BigDye Terminators and the ABI Prism 3100 sequencer
(Applied Biosystems).
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